SCHEMBL21330627

SCHEMBL21330627

Cc1ccc(Oc2cccc(F)n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 1/20 0.47
ATM Q13315 1/20 0.47
MAP4K4 O95819 1/20 0.45
P2RX3 P56373 5/20 0.43
F2 P00734 1/20 0.42
F10 P00742 1/20 0.42
PRSS1 P07477 1/20 0.42
PRSS2 P07478 1/20 0.42
PRSS3 P35030 1/20 0.42
ST14 Q9Y5Y6 1/20 0.42
FPR2 P25090 1/20 0.41
SCN9A Q15858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21330640 0.85 MEN1 (0.48) MEN1KMT2ANPC1ALDH1A1HTT
SCHEMBL8941507 0.85 MEN1 (0.50) MEN1KMT2AALDH1A1HTTP2RX3
SCHEMBL8941674 0.82 F2 (0.46) NPC1ALDH1A1HTTRAB9AMAP4K4
SCHEMBL21330612 0.81 MEN1 (0.51) MEN1KMT2AHTTP2RX3
SCHEMBL11684536 0.81 MEN1 (0.47) MEN1KMT2AALDH1A1F2F10
SCHEMBL10546373 0.81 MEN1 (0.55) MEN1KMT2ANPC1ALDH1A1HPGD
SCHEMBL9986917 0.81 F2 (0.39) MEN1KMT2AHTTP2RX3F2
SCHEMBL22061575 0.80 F2 (0.41) MAP4K4F2F10PRSS1PRSS2
SCHEMBL7228289 0.79 KDM4E (0.47) F2F10PRSS1PRSS2PRSS3
SCHEMBL8941703 0.78 MEN1 (0.46) MEN1KMT2AP2RX3FPR2SCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4265607-A1 AMINOPYRIDINE COMPOUND AND APPLICATION THEREOF Medshine Discovery Inc. (CN) 2023-10-25 EP disclosed
US-11739090-B2 Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors JUMBO DRUG BANK CO., LTD. (CN) 2023-08-29 US disclosed
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2020-07-14 US disclosed
CN-108069974-B Selective Bruton tyrosine kinase inhibitor and application thereof HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) 2019-12-10 CN disclosed
EP-3543239-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2019-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190276461-A1 SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF BTK, BMX, KCNK10 MEN1 2111/4885KMT2A 2028/4885NPC1 3441/4885
US-10711006-B2 Selective Bruton's tyrosine kinase inhibitor and use thereof BTK, SYK, LYN MEN1 2441/4885KMT2A 1652/4885NPC1 3687/4885
US-11739090-B2 Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors BTK, SYK, LCK MEN1 3580/4885KMT2A 1568/4885NPC1 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.